Current and historical daily PE Ratio for LGND (
Ligand Pharmaceuticals Inc
) from 1995 to Apr 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Ligand Pharmaceuticals stock (LGND) PE ratio as of Apr 16 2024 is 27.81.
More Details
Ligand Pharmaceuticals Inc (LGND) PE Ratio (TTM) Chart
Ligand Pharmaceuticals Inc (LGND) PE Ratio (TTM) Historical Data
View and export this data going back to 1995. Start your Free Trial
Total 1208
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Ligand Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-16 | 27.7 | 2024-02-09 | 26.2 |
| 2024-04-15 | 27.5 | 2024-02-08 | 26.0 |
| 2024-04-12 | 28.1 | 2024-02-07 | 25.7 |
| 2024-04-11 | 28.1 | 2024-02-06 | 26.0 |
| 2024-04-10 | 27.9 | 2024-02-05 | 25.8 |
| 2024-04-09 | 28.1 | 2024-02-02 | 25.7 |
| 2024-04-08 | 27.4 | 2024-02-01 | 25.6 |
| 2024-04-05 | 26.9 | 2024-01-31 | 25.2 |
| 2024-04-04 | 26.9 | 2024-01-30 | 25.5 |
| 2024-04-03 | 25.8 | 2024-01-29 | 25.9 |
| 2024-04-02 | 25.2 | 2024-01-26 | 26.4 |
| 2024-04-01 | 25.4 | 2024-01-25 | 26.0 |
| 2024-03-28 | 25.2 | 2024-01-24 | 25.6 |
| 2024-03-27 | 24.6 | 2024-01-23 | 25.4 |
| 2024-03-26 | 23.7 | 2024-01-22 | 25.3 |
| 2024-03-25 | 23.9 | 2024-01-19 | 25.0 |
| 2024-03-22 | 24.5 | 2024-01-18 | 24.6 |
| 2024-03-21 | 25.2 | 2024-01-17 | 24.4 |
| 2024-03-20 | 25.2 | 2024-01-16 | 24.5 |
| 2024-03-19 | 24.9 | 2024-01-12 | 25.0 |
| 2024-03-18 | 24.9 | 2024-01-11 | 24.9 |
| 2024-03-15 | 24.5 | 2024-01-10 | 25.4 |
| 2024-03-14 | 24.8 | 2024-01-09 | 25.3 |
| 2024-03-13 | 25.1 | 2024-01-08 | 25.6 |
| 2024-03-12 | 24.9 | 2024-01-05 | 24.4 |
| 2024-03-11 | 24.9 | 2024-01-04 | 24.3 |
| 2024-03-08 | 25.4 | 2024-01-03 | 24.1 |
| 2024-03-07 | 25.0 | 2024-01-02 | 24.9 |
| 2024-03-06 | 25.1 | 2023-12-29 | 24.6 |
| 2024-03-05 | 25.5 | 2023-12-28 | 24.8 |
| 2024-03-04 | 26.3 | 2023-12-27 | 87.1 |
| 2024-03-01 | 27.1 | 2023-12-26 | 87.5 |
| 2024-02-29 | 27.4 | 2023-12-22 | 86.2 |
| 2024-02-28 | 29.1 | 2023-12-21 | 85.3 |
| 2024-02-27 | 30.8 | 2023-12-20 | 83.5 |
| 2024-02-26 | 25.7 | 2023-12-19 | 84.6 |
| 2024-02-23 | 26.2 | 2023-12-18 | 83.4 |
| 2024-02-22 | 25.4 | 2023-12-15 | 81.1 |
| 2024-02-21 | 25.1 | 2023-12-14 | 81.6 |
| 2024-02-20 | 25.0 | 2023-12-13 | 81.1 |
| 2024-02-16 | 25.4 | 2023-12-12 | 75.8 |
| 2024-02-15 | 25.7 | 2023-12-11 | 75.3 |
| 2024-02-14 | 25.4 | 2023-12-08 | 74.5 |
| 2024-02-13 | 24.5 | 2023-12-07 | 74.0 |
| 2024-02-12 | 26.1 | 2023-12-06 | 72.0 |
Ligand Pharmaceuticals Inc (LGND) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Ligand Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US53220K5048
Share Class Description:
LGND: Ordinary Shares - Class BDescription
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers